<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00213746</url>
  </required_header>
  <id_info>
    <org_study_id>2003/011/HP</org_study_id>
    <nct_id>NCT00213746</nct_id>
  </id_info>
  <brief_title>Evaluation of Myocardial Viability by Means of Low-dose Dobutamine Gated SPECT (the DOGS Study)</brief_title>
  <official_title>Prediction of Left Ventricular Function Changes Using Low Dose Dobutamine Gated SPECT in Patients Referred for Viability Assessment: The DOGS (DObutamine Gated Spect)Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fédération Française de Cardiologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Société Française de Cardiologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Société Française de Médecine Nucléaire</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Viability assessment remains a clinical challenge in patient with coronary artery disease and
      left ventricular dysfunction. Several imaging modalities are available for evaluating
      myocardial viability, based either on perfusion or on contractile reserve analysis. Briefly,
      perfusion analysis is highly sensitive and contractile reserve highly specific. A combined
      analysis of both perfusion and contractile reserve has been proposed to improve the
      diagnostic accuracy in patient referred for a revascularization procedure. However, the value
      of this combined analysis has not been validated in unselected patients referred for
      viability assessment.

      The patients enrolled in the study will undergo a nitrate enhanced rest gated SPECT using a
      Tc-99m labeled tracer (sestamibi or tetrofosmine) followed by a second gated SPECT acquired
      during a low-dose dobutamine infusion (10 mcg/kg/mn). All patients will have a 6-month
      clinical and imaging follow-up, including physical examination and a nitrate enhanced rest
      gated SPECT using the same radiopharmaceutical. All treatments received during this 6-month
      period will be recorded, including medical therapy and coronary revascularization
      (angioplasty, stenting and CABG).

      Finally, the value of baseline perfusion and contractile reserve analysis in predicting left
      ventricular ejection fraction changes at 6-month follow-up will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date>December 2005</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment>75</enrollment>
  <condition>Coronary Arteriosclerosis</condition>
  <condition>Heart Failure, Congestive</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Myocardial Stunning</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consists with patients with documented coronary artery disease and
        left ventricular dysfunction (LVEF &lt; 50%)referred to aNuclear Medicine department for
        myocardial viability assessment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented coronary artery disease

          -  Left ventricular dysfunction (LVEF &lt; 50%)

          -  Patients referred to the Nuclear Medicine department for myocardial viability
             assessment

          -  Sinus Rhythm

          -  Acceptance of a 6-month follow-up

          -  Signed informed consent

        Exclusion Criteria:

          -  Recent acute coronary syndrome (&lt; 21 days)

          -  Atrial Fibrillation or significant arrhythmias

          -  Implanted pacemaker

          -  Contra indication to dobutamine

          -  Non ischaemic cardiomyopathy

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain Manrique, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Rouen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre-Yves Marie, MD</last_name>
    <role>Study Director</role>
    <affiliation>Central Hospital, Nancy, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe Franken, MD</last_name>
    <role>Study Director</role>
    <affiliation>Free University of Brussels</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AZ-VUB</name>
      <address>
        <city>Brussels</city>
        <zip>B 1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Caen</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Sud-Francilien</name>
      <address>
        <city>Corbeil</city>
        <zip>91100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol. 2002 Apr 3;39(7):1151-8.</citation>
    <PMID>11923039</PMID>
  </reference>
  <reference>
    <citation>Everaert H, Vanhove C, Franken PR. Effects of low-dose dobutamine on left ventricular function in normal subjects as assessed by gated single-photon emission tomography myocardial perfusion studies. Eur J Nucl Med. 1999 Oct;26(10):1298-303.</citation>
    <PMID>10541828</PMID>
  </reference>
  <reference>
    <citation>Everaert H, Vanhove C, Franken PR. Effect of beta-blockade on low-dose dobutamine-induced changes in left ventricular function in healthy volunteers: assessment by gated SPET myocardial perfusion scintigraphy. Eur J Nucl Med. 2000 Apr;27(4):419-24.</citation>
    <PMID>10805115</PMID>
  </reference>
  <reference>
    <citation>Leoncini M, Sciagrà R, Maioli M, Bellandi F, Marcucci G, Sestini S, Chiocchini S, Dabizzi RP. Usefulness of dobutamine Tc-99m sestamibi-gated single-photon emission computed tomography for prediction of left ventricular ejection fraction outcome after coronary revascularization for ischemic cardiomyopathy. Am J Cardiol. 2002 Apr 1;89(7):817-21.</citation>
    <PMID>11909565</PMID>
  </reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>June 17, 2013</last_update_submitted>
  <last_update_submitted_qc>June 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Arteriosclerosis</keyword>
  <keyword>Heart Failure, Congestive</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Myocardial Revascularization</keyword>
  <keyword>Tomography, Emission-Computed, Single-Photon</keyword>
  <keyword>Dobutamine</keyword>
  <keyword>Myocardial Stunning</keyword>
  <keyword>Myocardial Hibernation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Myocardial Stunning</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dobutamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

